Ada Website Helper

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Non-compete agreements should be banned, says President Biden

    February 8, 2023

    Microsoft’s AI-Powered Bing Comes to Google’s Bard-Powered Search

    February 7, 2023

    Google Launches AI Chatbot Bard To Compete With ChatGPT

    February 6, 2023
    Facebook Twitter Instagram
    Ada Website Helper
    • Home
    • Autism

      Autism diagnosis rates have tripled in the last 16 years, says new study

      February 2, 2023

      Autism provider AnswersNow raises $11 million to expand state footprint

      February 2, 2023

      Autism Awareness Comes to Lawrence Police Headquarters – Trentonian

      February 2, 2023

      A felon charged with impersonating a therapist at Michigan autism treatment center ordered to trial

      February 2, 2023

      Autism Society Philippines and SM Cares Meet on Autism

      February 2, 2023
    • Disabilities

      Litigation improves accessibility to voters for people with print disabilities.news

      February 2, 2023

      Stress Relief and Mental Health Support

      February 2, 2023

      ‘Extraordinary’ Court Order Granted To Allow Severely Disabled Women To Attend Neurology Appointments – The Irish Times

      February 2, 2023

      Community Public Heath Liaison – Disability Scoop Jobs

      February 2, 2023

      People with disabilities in rural areas struggle to recover from recession | Conversation

      February 2, 2023
    • Disability

      Southern District of Georgia | Lawrence County man pays reparations and could face federal jail for disability fraud

      February 2, 2023

      Hitting the Snow with New Courses on Accessibility and Disability Justice

      February 2, 2023

      ASBMB Calls for Broad Federal Efforts to Support Scientists with Disabilities

      February 2, 2023

      State abortion bans based on gender, disability, or race are not a remedy for eugenics, paper says

      February 2, 2023

      New Guidance on Hearing Impairment in the Workplace – Monterey Herald

      February 2, 2023
    • Literature

      Seattle Department of Arts and Culture Names 2023-2024 Seattle Citizen Poet Xin Yu Pai

      February 2, 2023

      ‘Correct Prison Manual’: Female Baloch Inmates Released After Passing Baloch Literature Exam

      February 2, 2023

      Researchers use AI to make texts thousands of years old readable

      February 2, 2023

      “Dream in the Crimson Room” is performed as toe art

      February 2, 2023

      Literature and books: Portsmouth news and information (Portsmouth)

      February 2, 2023
    • Living

      Delicious Living Magazine double winner for Kiss My Faces Moisture Shave at the 2023 Beauty & Body Awards.

      February 2, 2023

      Tracy’s tutor sells Christine Quinn’s house in Sunset

      February 2, 2023

      The man lived in a garage before filming in Opa Locka

      February 2, 2023

      Barcaro Buffalo Living & Commerce Announces Pace Strength and Conditioning as New Tenant

      February 2, 2023

      Self Help – Estes Park Trail Gazette

      February 2, 2023
    • Society

      The Outer Banks Voice – Phi Island Preservation Society Announces Three Events Celebrating Black History

      February 2, 2023

      Peninsula Humane Society & SPCA Pet of the Week: Kesha and Gosha

      February 2, 2023

      SML Chapter of Antique and Classic Boat Association Holds Winter Workshop

      February 2, 2023

      Ida B. Wells Society moves from UNC-Chapel Hill to Morehouse College

      February 2, 2023

      Wilton Historical Society Weekend Workshop

      February 2, 2023
    Facebook Twitter Instagram
    Ada Website Helper
    Home»Literature»Examples from the Gynecologic Cancer Literature
    Literature

    Examples from the Gynecologic Cancer Literature

    adawebsitehelper_ts8fwmBy adawebsitehelper_ts8fwmJanuary 12, 20236 Mins Read
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    In recent years, prospective and retrospective analyzes of non-randomized, population-based data have attracted significant interest among cancer researchers, third-party payers, regulators, and health policy professionals. Enhancing the value of Phase 3 clinical trial data.

    The success of efforts to critically analyze the unique contributions of specific components of care through the conduct of randomized trials, with the exception of the approach explored in the experimental arm of the trial, has been limited to the relative uniformity is required. Therefore, in such trials, patients with common, clinically relevant but potentially confounding comorbidities (e.g., history of severe mild or moderate cardiac, renal, or hepatic abnormalities) are routinely excluded from study enrollment. A concern here is that when other medical conditions are present, it may be more difficult to unambiguously assess the specific impact of the research approach on objective measures of efficacy such as survival and toxicity. However, because of well-recognized differences in characteristics between research subjects and individuals who receive regular care outside of clinical trials, well-designed testing of ‘real-world’ populations may It may provide a better picture of the real-world impact of clinical trials. Specific therapeutic intervention.

    While considerable attention has recently been paid to the differences between randomized trials and real-world views of cancer treatment, another potentially interesting approach to explore is the possibility of very similar or identical A comparison of the results of another randomized trial investigating the research question. Here, it is properly recognized that the randomized populations in individual studies may differ considerably from each other, so shouldn’t such cross-trial comparisons be conducted? , it is appropriate to acknowledge one of the classic warnings to clinical investigators that it should be performed with great care.

    But that’s exactly the point being emphasized here. Indeed, if the studies were essentially identical in design but reached different clinical conclusions, what does this observation tell us about the nature of the trial process and the interpretation of the results of the individual research studies? For example, consider the results of a well-designed, regulatory-quality clinical trial of an anti-cancer drug. These trials, at the time reported, have served as important components in establishing the standard of care in first-line chemotherapy management of epithelial cells. ovarian cancer.1,2

    The studies described below specifically examined the role of paclitaxel as a component of first-line anti-tumor drug therapy in this malignancy, following the remarkable demonstration of significant clinical activity of this drug in platinum-resistant disease.3 The first compared the standard treatment regimen (cisplatin + cyclophosphamide) with an experimental combination of cisplatin + paclitaxel infused over 24 hours.1 This landmark study found that paclitaxel-containing regimens improved overall survival (OS) when compared to the combination of cisplatin and cyclophosphamide. These data supported a regimen that has become standard of care practice for the use of platinum- and taxane-based primary cytotoxic strategies.Four The above study quickly closed its tally, and its survival outcomes were unknown at the time. Consequently, in the absence of such critical data, it was decided to initiate an additional study conducted by the same group of investigators in the Gynecologic Oncology Group with essentially identical eligibility and disqualification criteria. rice field. In this second study of his, a randomly assigned patient population received either cisplatin alone, paclitaxel alone, or the same combination regimen employed in the first trial of cisplatin and paclitaxel. We examined a slightly different clinical problem.

    There are some provocative questions that can be discussed in relation to the differences in the results of these two trials. Although this includes the impact of crossover from treatment with one of the two single agents to alternative antineoplastic agents, the specific points of this commentary are to emphasize that: Two landmark studies found fairly marked differences in OS between patient populations receiving the same combination chemotherapy regimen of cisplatin and paclitaxel.1,2

    In the first trial, the median OS for combination regimens containing paclitaxel was 38 months. A second trial, conducted shortly after the development of the first trial was completed, found that treatment with this same regimen was employed in trials conducted by the same group of clinicians/clinical investigators and followed essentially the same entry criteria. (Eligibility and Ineligibility) applied. Median OS was 26.3 months, with a difference in survival of nearly 1 year.

    Is there an explanation for this surprising and clinically difficult to ignore reduction in median OS associated with administration of the platinum/taxane combination regimen? , it is important to recognize the fact that, despite the fact that the clinical care of the two populations was provided by the same group of oncologists, they were separate trials with patients randomly assigned at different times.

    Certain hypotheses can be made about the main reason for the difference in OS between the two studies. When the first primary ovarian cancer paclitaxel trial began, there was considerable and pertinent concern about the drug’s potential serious cardiac effects, with early trials reporting sudden deaths. , the earliest patients enrolled in this randomized study required active cardiac monitoring when a 24-hour paclitaxel infusion was initiated. Significantly decreased as a result of toxicity profile.

    Due to previous concerns, we speculate that the first study population had an overall lower cardiovascular risk background (as a result of patient selection or physician recommendation) compared to the second study population. is reasonable. Moreover, the selection of patients for the second study occurred at a time when concerns about the severity of potential adverse cardiotoxicity were diminished. And the slightly inferior median OS in the second study was due, at least in part, to the presence of individuals with associated comorbidities (such as diabetes, mild renal impairment, and cerebrovascular disease). may be related to the relative increase in A woman with ovarian cancer.

    Finally, this now classic experience serves as a highly relevant example of the dangers of attempting to directly compare survival outcomes in different groups of patients in the absence of adequate trial-based randomization. It should help.

    References

    1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin vs. paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med1996;334(1):1-6. doi:10.1056/NEJM199601043340101
    2. Muggia FM, Braly PS, Brady MF et al Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Onkol2000;18(1):106-115. doi:10.1200/JCO.2000.18.1.106
    3. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: A unique anti-tumor agent with significant activity in advanced ovarian epithelial tumors. uninterned1989;111(4):273-279. Doi: 10.7326/0003-4819-111-4-273
    4. Armstrong DK, Alvarez RD, Bax FJ, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw2022;20(9):972-980.doi:10.6004/jnccn.2022.0047



    Source link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    adawebsitehelper_ts8fwm
    • Website

    Related Posts

    Literature February 2, 2023

    Seattle Department of Arts and Culture Names 2023-2024 Seattle Citizen Poet Xin Yu Pai

    Literature February 2, 2023

    ‘Correct Prison Manual’: Female Baloch Inmates Released After Passing Baloch Literature Exam

    Literature February 2, 2023

    Researchers use AI to make texts thousands of years old readable

    Literature February 2, 2023

    “Dream in the Crimson Room” is performed as toe art

    Literature February 2, 2023

    Literature and books: Portsmouth news and information (Portsmouth)

    Literature February 2, 2023

    Latinx Visions Conference at UNM : UNM Newsroom

    Leave A Reply Cancel Reply

    Don't Miss
    News February 8, 2023

    Non-compete agreements should be banned, says President Biden

    Joe Biden mentioned hamburgers in his 2023 State of the Union address. Specifically, the president…

    Microsoft’s AI-Powered Bing Comes to Google’s Bard-Powered Search

    February 7, 2023

    Google Launches AI Chatbot Bard To Compete With ChatGPT

    February 6, 2023

    Google releases new AI chatbot Bard to compete with ChatGPT

    February 6, 2023
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    About Us

    This website provides information about disability and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Our Picks

    Non-compete agreements should be banned, says President Biden

    February 8, 2023

    Microsoft’s AI-Powered Bing Comes to Google’s Bard-Powered Search

    February 7, 2023

    Google Launches AI Chatbot Bard To Compete With ChatGPT

    February 6, 2023

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    Facebook Twitter Instagram Pinterest
    • Home
    • Contact us
    • DMCA
    • Privacy Policy
    © 2023 adawebsitehelper. Designed b yadawebsitehelper.

    Type above and press Enter to search. Press Esc to cancel.